Retrieve available abstracts of 15 articles: HTML format
Single Articles
September 2025
NAIK V, Nekkalapudi A, Boopathy AV, Falkard B, et al Emergence of in vitro resistance to lenacapavir is similar across HIV-1 subtypes.
AIDS. 2025 Sep 18. doi: 10.1097/QAD.0000000000004334. PubMedAbstract available
June 2025
MERAD Y, Mariaggi AA, Karmochkine M, Slama L, et al Virological success despite archived INSTI drug resistance mutations on
INSTI-based antiretroviral regimens.
AIDS. 2025 Jun 5. doi: 10.1097/QAD.0000000000004251. PubMedAbstract available
May 2025
CLEMENTE T, Bellomo M, Raccagni AR, Lolatto R, et al Sexually transmitted infections in men who have sex with men with
tenofovir/emtricitabine- or cabotegravir-resistant HIV.
AIDS. 2025 May 3. doi: 10.1097/QAD.0000000000004225. PubMedAbstract available
April 2025
ZHANG R, Chung SL, Lee SS, Wong NS, et al Prevalence and resistance patterns of Mycoplasma genitalium infection in people
living with HIV: a systematic review and meta-analysis.
AIDS. 2025 Apr 22. doi: 10.1097/QAD.0000000000004219. PubMedAbstract available
GLENN JS, Bennett A, Mackie N, Lyall H, et al The cumulative prevalence of HIV-1 drug resistance in perinatal HIV.
AIDS. 2025 Apr 4. doi: 10.1097/QAD.0000000000004202. PubMedAbstract available
March 2025
MUCCINI C, Spagnuolo V, Zazzi M, Castagna A, et al People with four-class drug-resistant HIV-1 may have low levels of intact DNA.
AIDS. 2025;39:475-476. PubMedAbstract available
INZAULE S, Jordan MR, Fokam J, Hamers RL, et al Non-canonical HIV drug resistance mutations: need to close existing gaps.
AIDS. 2025 Mar 6. doi: 10.1097/QAD.0000000000004170. PubMedAbstract available
February 2025
WAGNER T, Levy I, Wieder-Finesod A, Wax M, et al Drug resistance testing at regimen failure in individuals diagnosed with HIV-1
between 2010 and 2018 in Israel.
AIDS. 2025 Feb 3. doi: 10.1097/QAD.0000000000004138. PubMedAbstract available
October 2024
ENI-OLUTU A, Mackie NE, Glenn J, Bailey A, et al Emerging integrase resistance in an international perinatal virtual clinic.
AIDS. 2024 Oct 28. doi: 10.1097/QAD.0000000000004048. PubMedAbstract available
CLEMENTE T, Pontillo D, Malagnino V, Calza L, et al Cancer in people with multidrug-resistant HIV.
AIDS. 2024;38:1801-1806. PubMedAbstract available
September 2024
ZANIEWSKI E, Skrivankova VW, Brazier E, Avihingsanon A, et al Transition to dolutegravir-based ART in 35 low- and middle-income countries: a
global survey of HIV care clinics.
AIDS. 2024 Sep 5. doi: 10.1097/QAD.0000000000004007. PubMedAbstract available
BURGER D, Wttewaal E, Oosterhof P, Stalenhoef J, et al Concomitant use of anabolic androgen steroids and cabotegravir/rilpivirine
leading to virological failure and development of two-class resistance.
AIDS. 2024;38:1728-1729. PubMed
July 2024
KARABAY O Concerns and clarifications regarding the article 'Virological, weight, and drug
resistance outcomes among patients initiating a dolutegravir-based first line ART
regimen in Zimbabwe'.
AIDS. 2024;38:1273. PubMed
March 2024
PAPAIOANNU BORJESSON R, Galli L, Lolatto R, Menzaghi B, et al Lower aids-related hospitalizations in women living with HIV multidrug
resistance.
AIDS. 2024;38:435-438. PubMed
February 2024
GONCALVES P, Barreto J, Santos M, Leal S, et al HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde,
2019-2021.
AIDS. 2024 Feb 13. doi: 10.1097/QAD.0000000000003866. PubMedAbstract available